#AACR20: Ear­ly da­ta sug­gest No­var­tis' In­cyte-dis­cov­ered MET in­hibitor helps lung can­cer pa­tients with brain le­sions

Months af­ter cap­ma­tinib — the MET in­hibitor de­signed to cross the blood-brain bar­ri­er dis­cov­ered by In­cyte and li­censed by No­var­tis — se­cured the FDA’s pri­or­i­ty re­view in pa­tients with a form of lung can­cer, the Swiss drug­mak­er has re­port­ed en­cour­ag­ing, al­beit ear­ly, da­ta in pa­tients whose can­cer had spread to the brain.

Da­ta from 13 pa­tients with metasta­t­ic MET ex­on 14 skip­ping non-small cell lung can­cer with brain metas­tases, were un­veiled at the vir­tu­al­ly-held Amer­i­can As­so­ci­a­tion for Can­cer Re­search con­fer­ence on Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER